Table 1 The baseline characteristics of the RA patients who received tofacitinib or baricitinib

Age (years)

50.0 (33.0–58.8)

50.0 (42.5–56.5)

0.48

Sex, n (% female)

63 (85.1%)

86 (81.9%)

0.57

RA duration (months)

12.0 (7.0–36.0)

12.0 (6.0–60.0)

0.82

glucocorticoid dosage at baseline(mg)

2.0(0–4.0)

0(0–4.0)

0.14

Number of patients with previous use of DMARDs

1 class

31(41.9%)

50(47.6%)

0.49

2 classes

38(51.4%)

51(48.6%)

0.71

3 classes

5(6.8%)

4(3.8%)

0.37

Hyperuricemia (n)

2(2.7%)

0

0.09

Type II diabetes(n)

1(1.4%)

2(1.9%)

0.78

Hyperlipemia(n)

0

2(1.9%)

0.23

Latent tuberculosis infection(n)

2(2.7%)

3(2.9%)

0.95

Hypertension(n)

0

2(1.9%)

0.64

Hepatitis B indicates antigen carriage(n)

4(5.4%)

4(3.8%)

0.61

TJC

6.0 (2.0–11.8)

6.0 (2.0–12.0)

0.36

SJC

5.5 (2.0–12.0)

6.0 (2.0–12.0)

0.57

VAS

5.5 (4.0–8.0)

5.5 (3.0–8.0)

0.28

DAS28-CRP

4.6 (3.7–6.2)

4.9 (3.7–6.0)

0.72

WBC (×10⁹/L)

7.5 (6.7–9.8)

7.3 (6.1–9.4)

0.36

HGB (g/L)

113.7 ± 15.2

116.8 ± 11.5

0.11

PLT (×10⁹/L)

331.7 (271.0–434.7)

334.7 (274.0–423.8)

0.91

NEU (×10⁹/L)

5.3 (4.2–6.9)

5.0 (3.8–6.7)

0.54

LYM (×10⁹/L)

1.8 (1.3–2.2)

1.7 (1.3–2.0)

0.33

AST (U/L)

24.5 (19.0–30.0)

25.0 (21.0–29.5)

0.50

ALT (U/L)

12.0 (10.0–20.0)

14.0 (9.0–22.0)

0.78

CREA (µmol/L)

53.0 (46.0–65.8)

54.0 (46.5–65.0)

0.64

CRP (mg/L)

16.9 (4.9–53.9)

22.7 (8.3–61.4)

0.46

RF positive

67(90.5%)

94(91.3%)

0.90

ESR (mm/h)

57.5 (35.0–82.8)

62.0 (40.0–91.0)

0.23